202 related articles for article (PubMed ID: 36881132)
1. Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation.
Lin YS; Chiang SF; Chen CY; Hong WZ; Chen TW; Chen WT; Ke TW; Yang PC; Liang JA; Shiau AC; Chao KSC; Huang KC
Cancer Immunol Immunother; 2023 Jul; 72(7):2283-2297. PubMed ID: 36881132
[TBL] [Abstract][Full Text] [Related]
2. Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer.
Huang KC; Ke TW; Chen JY; Hong WZ; Chiang SF; Lai CY; Chen TW; Yang PC; Chen LC; Liang JA; Chen WT; Chao KSC
Sci Rep; 2023 Nov; 13(1):19440. PubMed ID: 37945630
[TBL] [Abstract][Full Text] [Related]
3. High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma.
Zhang B; Cheng B; Li FS; Ding JH; Feng YY; Zhuo GZ; Wei HF; Zhao K
Tumour Biol; 2015 Dec; 36(12):9411-9. PubMed ID: 26113408
[TBL] [Abstract][Full Text] [Related]
4. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
5. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
6. The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma.
Zhang B; Song B; Wang X; Chang XS; Pang T; Zhang X; Yin K; Fang GE
Tumour Biol; 2015 Jul; 36(7):5459-66. PubMed ID: 25677906
[TBL] [Abstract][Full Text] [Related]
7. CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C; Yin S; To KKW; Fu L
Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
[TBL] [Abstract][Full Text] [Related]
8. An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.
Zhang Y; Li Y; Zuo Z; Li T; An Y; Zhang W
Pathol Oncol Res; 2023; 29():1611016. PubMed ID: 36910014
[No Abstract] [Full Text] [Related]
9. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
Gou HF; Huang J; Shi HS; Chen XC; Wang YS
PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
[TBL] [Abstract][Full Text] [Related]
10. IRF1-mediated immune cell infiltration is associated with metastasis in colon adenocarcinoma.
Shao YJ; Ni JJ; Wei SY; Weng XP; Shen MD; Jia YX; Meng LN
Medicine (Baltimore); 2020 Sep; 99(37):e22170. PubMed ID: 32925784
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
[TBL] [Abstract][Full Text] [Related]
14. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
Jacoberger-Foissac C; Cousineau I; Bareche Y; Allard D; Chrobak P; Allard B; Pommey S; Messaoudi N; McNicoll Y; Soucy G; Koseoglu S; Masia R; Lake AC; Seo H; Eeles CB; Rohatgi N; Robson SC; Turcotte S; Haibe-Kains B; Stagg J
Cancer Immunol Res; 2023 Jan; 11(1):56-71. PubMed ID: 36409930
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma.
Chen LC; Yang PC; Chen CY; Chiang SF; Chen TW; Chen WT; Ke TW; Liang JA; Shiau AC; Chao KSC; Huang KC
J Cancer; 2024; 15(6):1750-1761. PubMed ID: 38370387
[TBL] [Abstract][Full Text] [Related]
17. Human plasmacytoid dendritic cells express the functional purinergic halo (CD39/CD73).
Sosa-Luis SA; Ríos-Ríos WJ; Almaraz-Arreortua A; Romero-Tlalolini MA; Aguilar-Ruiz SR; Valle-Ríos R; Sánchez-Torres C; Torres-Aguilar H
Purinergic Signal; 2024 Feb; 20(1):73-82. PubMed ID: 37055675
[TBL] [Abstract][Full Text] [Related]
18. Regulatory role of CD39 and CD73 in tumor immunity.
Kaplinsky N; Williams K; Watkins D; Adams M; Stanbery L; Nemunaitis J
Future Oncol; 2024 Apr; ():. PubMed ID: 38652041
[TBL] [Abstract][Full Text] [Related]
19. [High expression of ANKRD6 is an indicator for poor prognosis of colon adenocarcinoma].
Zhao H; Liu G; Li Y; Yang N; Zhao J
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Oct; 43(10):1715-1724. PubMed ID: 37933647
[TBL] [Abstract][Full Text] [Related]
20. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X; Xie L
J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
